AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treat...
Main Authors: | Yi Zhao, Yi Yang, Yunhua Xu, Shun Lu, Hong Jian |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-04-01
|
Series: | FEBS Open Bio |
Subjects: | |
Online Access: | https://doi.org/10.1002/2211-5463.12162 |
Similar Items
-
PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01) -
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
by: Poh ME, et al.
Published: (2023-01-01) -
Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
by: Tianxiang Chen, et al.
Published: (2019-04-01) -
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
by: Savvas Papageorgiou, et al.
Published: (2022-07-01) -
The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine
by: Malinda Itchins, et al.
Published: (2022-08-01)